KALA BIO, Inc.
LSE: 0JQ2.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Avi Minkowitz
- Employees
- 38
- Headquarters
- Arlington, United States
- IPO year
- 2018
- Market cap
- $491.5K
- Website
- https://www.kalarx.com
Loading 0JQ2…
Loading profile data…Frequently asked questions about 0JQ2
What does KALA BIO, Inc. (0JQ2.L) do?
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in...
Where does 0JQ2.L trade?
KALA BIO, Inc. (0JQ2.L) trades on the London Stock Exchange.
What sector is 0JQ2.L in?
KALA BIO, Inc. (0JQ2.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of KALA BIO, Inc.?
Avi Minkowitz is the chief executive officer of KALA BIO, Inc. (0JQ2.L).
Where is KALA BIO, Inc. headquartered?
KALA BIO, Inc. is headquartered in United States.
Does 0JQ2.L pay a dividend?
KALA BIO, Inc. (0JQ2.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0JQ2.L go public?
KALA BIO, Inc. (0JQ2.L) completed its initial public offering in 2018.